Sarcopenia Treatment Market

Industry Insights-

• The Global Sarcopenia Treatment Market was valued at USD 262.9 Million in 2020
• It is anticipated to reach USD 377.6 Million in 2027
• A CAGR of 5.87% is anticipated over the forecast period

Overview-

Sarcopenia is a type of muscle loss (muscle atrophy) that occurs with aging and/or immobility. It is characterized by the degenerative loss of skeletal muscle mass, quality, and strength. The rate of muscle loss is dependent on exercise level, co-morbidities, nutrition and other factors. Sarcopenia can lead to reduced quality of life and disability. It involves the loss of muscle mass and strength due to natural aging process.

This condition affects the gait and overall ability of body to perform normal tasks. According to International Osteoporosis Foundation (IOF), the muscle loss starts from the age of 40. The major causes of sarcopenia could be sedentary lifestyle, malnutrition and unhealthy food intake. As the prevalence of sarcopenia is high among the older population, many manufacturers are focusing on research and development of drugs to treat sarcopenia.

Covid-19 Impact-

Covid-19 has witnessed a positive impact on global sarcopenia treatment market as increasing number of cases of sarcopenia as a deterioration of muscle mass and function (more likely in older populations) as well as increase in body fat due to lockdowns restrictions. Due to limitations and distancing policy during Covid-19, there is a reduction in physical activity & changes in dietary intakes that have the potential to accelerate sarcopenia.

Key Players-

Some of the key players for global Sarcopenia Treatment Market are-

• Abbott Laboratories
• Nestle S.A.
• Pfizer Inc.
• Sanofi S.A.
• Bayer AG
• Zydus Cadila
• GlaxoSmithKline plc
• others

Segmentation Analysis-

By Supplement Type

• Protein Supplement
• Vitamin D Supplement
• Vitamin B12 Supplement
• Others

Based on supplement type, the global market is segmented as protein supplement, vitamin B12 supplement, vitamin D & calcium supplement, and others. The rising awareness about the importance of protein for muscle strengthening and the increasing demand for protein-rich diets are driving the growth of the global protein supplement market. The growing number of health-conscious consumers, rising disposable incomes, and the increasing prevalence of chronic diseases are further expected to drive the market. Additionally, the growing demand for plant-based and organic protein supplements is further expected to fuel market growth. Moreover, the rising trend of veganism and the growing number of athletes and bodybuilders are expected to further drive the demand for protein supplements.

By Distribution Channel

• Pharmacies
• Online
• Hypermarket & Supermarket
• Others

On the basis of distribution channel, the global market is segmented as hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment held the highest market share, driven by improved supply chain management and an increase in the number of hospitalized patients. Meanwhile, the online pharmacies category is expected to grow at the fastest CAGR, reflecting the rising popularity of online purchases due to their superior discount rates and patient convenience.

By Region:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Geographically, North America region is expected to dominate in the global sarcopenia treatment market. Due to the presence of developed healthcare facilities and technological advancements, the prevalence of sarcopenia is high among old age population in this region. For instance; as per the Population Reference Bureau, the number of Americans ages 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060, and the 65-and-older age group’s share of the total population will rise from 16% to 23%.

About 45% of older adults in the United States are affected by sarcopenia. In addition, there is a considerable economic burden of related healthcare expenditures for sarcopenia in the United States which is estimated to be USD 18.5 billion annually. The excess healthcare expenditures were $860 for every sarcopenia man and $933 for every sarcopenia woman. A 10% reduction in sarcopenia prevalence would result in savings of $1.1 billion (dollars adjusted to 2000 rate) per year in U.S. healthcare costs.

Asia Pacific region is expected to witness a significant growth in the global Sarcopenia market. This is due to the increasing geriatric population, increased research activities, and awareness in developing countries such as India and China. For instance; according to UNFPA report, the number of older people in the Asia-Pacific region is rising at an unprecedented rate and it is at the forefront of the global phenomenon of population ageing. By 2050, one in four people in Asia and the Pacific will be over 60 years old. The population of older persons (aged over 60) in the region will triple between 2010 and 2050, reaching close to 1.3 billion people.

Market Drivers-

Increasing prevalence of sarcopenia coupled with the growing geriatric population

The increasing prevalence of the geriatric population and the growing number of cases of sarcopenia among the old age population are the major factors driving the demand of the sarcopenia treatment. Sarcopenia is predominantly a geriatric condition, with a gradual loss of skeletal muscle mass and a loss of muscle function. It is one of the leading health issues in the older adults, and it increases disability risk, falls as well as injuries related to falls, hospitalization, limitation of independence, and mortality.

Nowadays, the number of sarcopenia cases in the geriatric population is increasing day by day and it is a big concern for different countries. For example; there are currently over 703 million people worldwide above the age of 65 years. With a gradual loss of skeletal muscle mass and a loss of muscle function the problem of sarcopenia is increasing in the geriatric population. According to the World Health Organization; by 2050; the world’s population aged 60 years and above is expected to reach 2 billion from 900 million in 2015. Moreover, the conferences, meetings held by the foundations help to expand and share the knowledge and information about sarcopenia treatment which will, in turn, drives the growth of the sarcopenia treatment market.

For instance; the U.S. Food and Drug Administration held its public meeting on Patient-Focused Drug Development for sarcopenia in April 2017. The focus of the meeting was to acquire patient perspectives on symptoms and the daily impacts of their condition. The loss of muscle tissue may progress more rapidly when a person reaches their 60s and 70s.

Market Opportunities-

Increasing investment in research and development to develop more effective therapies to treat Sarcopenia to create opportunities

increasing investment in research and development to develop more effective therapies to treat Sarcopenia is expected to drive the sarcopenia treatment market growth. For instance; on March 1st, 2018; BIOPHYTIS demonstrated results of Sarconeos (BIO101) for treating sarcopenia, and announced patient enrolment for the SARA-INT international clinical study, at the 8th International Conference on Frailty & Sarcopenia Research (ICFSR).

BIOPHYTIS, announced that it will present four posters and will give two oral presentations in the treatment of Sarcopenia at the 8th International Conference on Frailty & Sarcopenia Research. These results demonstrate the strong potential of Sarconeos (BIO101) in the treatment of Sarcopenia and confirm the relevance of the SARA-INT international clinical study, in which the first patient will be enrolled in the coming weeks. Furthermore, increasing R&D activities by the manufacturers for the development of new nutrition supplements is also expected to drive the sarcopenia treatment market in upcoming years.

Recent Developments-

• In February 2022, MyMD Pharmaceuticals announced the encouraging results of its pre-Phase II Trial of MYMD-1, a novel immunotherapy drug designed to slow the aging process, prevent sarcopenia and frailty, and extend a healthy lifespan. The clinical data showed that the drug candidate was safe and had promising efficacy in the patient population.
• In January 2022, the USPTO granted MyMD Pharmaceuticals, Inc. Patent 11,219,620 B2, titled “Method of Treating Sarcopenia.”

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2020:	USD 262.9 Million
Base year considered	2020
Forecast Period CAGR %:	5.87 %
Market Size Expected in 2027:	USD 377.6 Million
Tables, Charts & Figures:	175
Pages	200
Key Players/Companies	Abbott Laboratories,Nestle S.A., Pfizer Inc., Sanofi S.A., Bayer AG, Zydus Cadila, GlaxoSmithKline plc, others.
Segments Covered	By Supplement Type, By Distribution Channel
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa